Edesa Biotech is trading at $4.65, with a -5.87% change amid a recent financing overhang.

  • No new company-specific announcement explaining the August 27 decline was identified.
  • The move contrasts with higher midday levels for the S&P 500, Nasdaq Composite, and Dow Jones.
  • Edesa priced a $25 million public offering at $5.50 per unit; Velan Capital disclosed a 9.99% stake.